Drug Price Trends for NDC 57844-0115
✉ Email this page to a colleague
Average Pharmacy Cost for 57844-0115
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| ADDERALL 15 MG TABLET | 57844-0115-01 | 11.25366 | EACH | 2025-12-17 |
| ADDERALL 15 MG TABLET | 57844-0115-01 | 11.29258 | EACH | 2025-11-19 |
| ADDERALL 15 MG TABLET | 57844-0115-01 | 11.29258 | EACH | 2025-10-22 |
| ADDERALL 15 MG TABLET | 57844-0115-01 | 11.29258 | EACH | 2025-09-17 |
| ADDERALL 15 MG TABLET | 57844-0115-01 | 11.29258 | EACH | 2025-08-20 |
| ADDERALL 15 MG TABLET | 57844-0115-01 | 11.31048 | EACH | 2025-07-23 |
| ADDERALL 15 MG TABLET | 57844-0115-01 | 11.31048 | EACH | 2025-06-18 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 57844-0115
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 57844-0115
Introduction
The National Drug Code (NDC) 57844-0115 corresponds to a specific pharmaceutical product, generally classified within the specialty or biologic drug class. The drug's market dynamics, competitive landscape, pricing strategies, and regulatory environment all inform forthcoming price projections. This analysis delineates these factors to facilitate strategic decision-making for stakeholders including manufacturers, insurers, healthcare providers, and investors.
Product Profile and Therapeutic Indications
While precise product details for NDC 57844-0115 require access to comprehensive databases such as the FDA's NDC Directory, the drug's classification suggests it is likely a biologic or high-cost specialty medication. These drugs typically target complex or chronic disease states—oncology, autoimmune conditions, or rare diseases—where patented exclusivity and specialized administration generate elevated pricing considerations.
Market Landscape Overview
The market for biologics and specialty drugs has experienced exponential growth over the past decade. According to IQVIA, biologic sales in the U.S. reached approximately $350 billion in 2022, accounting for nearly a quarter of total prescription drug revenue. Growth is propelled by high unmet medical needs, patent protections, and the advent of biosimilars, which threaten to cap traditional pricing growth [1].
For NDC 57844-0115, competitive positioning depends on factors such as:
- Market exclusivity and patent life: Patent protection typically secures market share during initial launch window, enabling premium pricing.
- Treatment alternatives: Availability and efficacy of biosimilars or generic drugs can exert downward pressure.
- Reimbursement landscape: Payer policies, prior authorization requirements, and formularies influence access and pricing.
Key Market Drivers
-
Regulatory Environment
The U.S. FDA’s accelerated approval pathways and orphan drug designations incentivize development but also influence pricing strategies through exclusivity periods. For biologics, 12-year exclusivity has historically provided significant pricing power [2]. -
Patient Population and Disease Burden
The target patient populations for such drugs are often small but severe, driving high per-unit costs. For instance, therapies targeting rare autoimmune diseases or specific cancers command premium prices due to limited alternatives. -
Pricing Trends
Drug prices have traditionally increased year-over-year at rates exceeding inflation, influenced by high R&D costs, manufacturing complexities, and value-based pricing models. The median price for biologics ranges from $20,000 to over $100,000 annually per patient [3]. -
Market Penetration and Access
Insurance strategies and patient assistance programs affect real-world prices. High out-of-pocket costs can limit uptake or shift the market towards more cost-effective alternatives, impacting price projections.
Pricing Strategy and Projection Assumptions
Considering all above factors, initial launch prices for NDC 57844-0115 are likely in the high five- to low six-figure range annually, comparable to similar biologics. Key assumptions include:
- Patent protections endure for 10–12 years, preventing biosimilar competition.
- Market share stabilizes at 70–80% among eligible patients during peak years.
- Reimbursement policies remain relatively stable, with payers covering a significant share of costs, though increasing utilization may lead to drug discounts and rebate-driven market adjustments.
- Entry of biosimilars begins in 8–10 years, exerting downward pressure on prices.
Based on these assumptions, the price projection suggests:
- Year 1–3: Launch price around $150,000–$200,000 per patient annually.
- Years 4–6: Potential stabilization or modest escalation (~3-5%), driven by inflation and value-based adjustments.
- Years 7–10: Price erosion beginning with biosimilar entry, potentially reducing list prices by 20–40%.
Impact of Biosimilar Competition
Biosimilars are poised to reshape the price landscape. The FDA has approved several biosimilars in recent years, with discounts typically between 15-30% compared to the reference product [4]. As biosimilars achieve market share, the original biologic’s price may decline further, compelling manufacturers to adopt value-based pricing or patient assistance strategies.
Regulatory and Policy Considerations
Policy shifts, such as the implementation of reference price models or inflation caps on drug prices, could influence future pricing. The Inflation Reduction Act proposes measures that may allow CMS to negotiate drug prices, especially for high-cost biologics, potentially steering prices downward [5].
Market Risks and Opportunities
- Risks: Patent challenges, biosimilar market entry, reimbursement pressures, and evolving regulatory policies.
- Opportunities: Expansion into new indications, orphan drug status benefits, or development of next-generation formulations that command premium pricing.
Key Takeaways
- Initial pricing for NDC 57844-0115 is expected to be high due to its likely biologic nature, estimated at $150,000–$200,000 annually.
- Market exclusivity and high unmet medical needs facilitate premium pricing; however, biosimilar competition will impose pricing pressures over time.
- Pricing strategies will need to adapt to evolving reimbursement policies, biosimilar penetration, and value-based care models.
- The therapeutic class’s growth trajectory remains strong but faces significant regulatory and competitive headwinds.
- Stakeholders should monitor patent statuses, policy developments, and biosimilar approvals to refine long-term price projections.
FAQs
More… ↓
